Vol. 4 No. 6 (2024): June
Reimbursement Recommendations

Bimekizumab (Bimzelx)

Published June 3, 2024

Key Messages

  • CADTH recommends that Bimzelx be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met.
  • Bimzelx should only be covered to treat adult patients with active PsA according to the reimbursement criteria used for other biologic disease-modifying antirheumatic drugs (bDMARDs) that are currently reimbursed by public drug plans.
  • Bimzelx should only be reimbursed if it is prescribed by a rheumatologist or a clinician who has experience treating adult patients with active PsA and if it does not cost more than the least expensive bDMARD reimbursed for the treatment of active PsA. Bimzelx should not be reimbursed when used together with other biologic or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) for active PsA.